Caprari F, Alfano A, Buzzetti G, et al. [Unmet clinical need and new therapeutic options.]. Recenti Prog Med. 2022;113(3):161-166. PMID:35315445

EFPIA. Let’s discuss the future of Unmet Medical Needs (UMN) in EU Policies. Report from a multi-stakeholder workshop (https://www.efpia.eu/media/fiveaumy/let-s-discuss-the-future-of-unmet-medical-needs.pdf) (Accessed August 2023).

Cleemput I, Devriese S, Christiaens W, Kohn L. Multi-criteria decision analysis for the appraisal of medical needs: a pilot study. Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE). 2016. KCE Reports 272. https://doi.org/10.57598/R272C (Accessed May 2023).

Cleemput I, Devriese S, Kohn L, Westhovens R. A multi-criteria decision approach for ranking unmet needs in healthcare. Health Policy. 2018;122(8):878-884. https://doi.org/10.1016/j.healthpol.2018.06.010 PMID:29983193 DOI: https://doi.org/10.1016/j.healthpol.2018.06.010

Lakdawalla D, Malani A, Reif J. The insurance value of medical innovation. J Public Econ. 2017;145:94-102. https://doi.org/10.1016/j.jpubeco.2016.11.012 DOI: https://doi.org/10.1016/j.jpubeco.2016.11.012

Angelis A, Kanavos P. Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework. Soc Sci Med. 2017;188:137-156. https://doi.org/10.1016/j.socscimed.2017.06.024 PMID:28772164 DOI: https://doi.org/10.1016/j.socscimed.2017.06.024

Murphy J, Coster G. Issues in patient compliance. Drugs. 1997;54(6):797-800. https://doi.org/10.2165/00003495-199754060-00002 PMID:9421690 DOI: https://doi.org/10.2165/00003495-199754060-00002

OECD. (2021), Health at a Glance 2021: OECD Indicators, OECD Publishing, Paris (https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2021_ae3016b9-en) (Accessed May 2023).

Vreman RA, Heikkinen I, Schuurman A, et al. Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions. Value Health. 2019;22(11):1275-1282. https://doi.org/10.1016/j.jval.2019.07.007 PMID:31708064 DOI: https://doi.org/10.1016/j.jval.2019.07.007

World Health Organization. Consitution. Online https://www.who.int/about/governance/constitution (Accessed May 2023).

Zhang K, Kumar G, Skedgel C. Towards a New Understanding of Unmet Medical Need. Appl Health Econ Health Policy. 2021;19(6):785-788. https://doi.org/10.1007/s40258-021-00655-3 PMID:34143420 DOI: https://doi.org/10.1007/s40258-021-00655-3

Kusynová Z, Pauletti GM, van den Ham HA, Leufkens HGM, Mantel-Teeuwisse AK. Unmet Medical Need as a Driver for Pharmaceutical Sciences - A Survey Among Scientists. J Pharm Sci. 2022;111(5):1318-1324. https://doi.org/10.1016/j.xphs.2021.10.002 PMID:34634318 DOI: https://doi.org/10.1016/j.xphs.2021.10.002

Tarantola A, Otto MH, Armeni P, Costa F, Malandrini F, Jommi C. Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case. J Pharm Policy Pract. 2023;16(1):67. https://doi.org/10.1186/s40545-023-00570-z PMID:37198599 DOI: https://doi.org/10.1186/s40545-023-00570-z

Reform of the EU pharmaceutical legislation. Online https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe/reform-eu-pharmaceutical-legislation_en (Accessed May 2023).

Determina AIFA n. 1535/2017 . Online https://www.aifa.gov.it/farmaci-innovativi) (Accessed May 2023).

Jommi C, Galeone C. The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency. PharmacoEconom Open. 2023;7(3):373-381. https://doi.org/10.1007/s41669-023-00393-3 PMID:36763319 DOI: https://doi.org/10.1007/s41669-023-00393-3

Fortinguerra F, Perna S, Marini R, Dell’Utri A, Trapanese M, Trotta F; Scientific & Technical Committee (Commissione Tecnico-Scientifica, CTS) of Italian Medicines Agency-AIFA. The Assessment of the Innovativeness of a New Medicine in Italy. Front Med (Lausanne). 2021;8:793640. https://doi.org/10.3389/fmed.2021.793640 PMID:34957163 DOI: https://doi.org/10.3389/fmed.2021.793640

Galeone C, Bruzzi P, Jommi C. Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system. BMJ Open. 2021;11(1):e041259. https://doi.org/10.1136/bmjopen-2020-041259 PMID:33441356 DOI: https://doi.org/10.1136/bmjopen-2020-041259

AIFA. Linee guida per la compilazione del dossier a supporto della domanda di rimborsabilità e prezzo di un medicinale ai sensi del d.m. 2 agosto 2019 - Versione 1.0 – 2020. (https://www.aifa.gov.it/documents/20142/1283800/Linee_guida_dossier_domanda_rimborsabilita.pdf) (Accessed May 2023).

AIFA. Accesso precoce al farmaco e uso off-label. Online https://www.aifa.gov.it/accesso-precoce-uso-off-label (Accessed May 2023).

Transparency Committee (HAS) doctrine. Principles of medicinal product assessments and appraisal for reimbursement purposes. 2020. Online https://www.has-sante.fr/upload/docs/application/pdf/2019-07/doctrine_de_la_commission_de_la_transparence_-_version_anglaise.pdf (Accessed May 2023).

Transparency Committee (HAS) doctrine. Authorisation for early access to medicinal products: HAS assessment doctrine. 2021. Online https://www.has-sante.fr/upload/docs/application/pdf/2021-08/authorisation_for_early_access_to_medicinal_products_has_assessment_doctrine.pdf) (Accessed May 2023).

UK Government Guidance. Early access to medicines scheme (EAMS): task group and principles. 2016. Online https://www.gov.uk/government/publications/early-access-to-medicines-scheme-eams-how-the-scheme-works/early-access-to-medicines-scheme-eams-task-group-and-principles (Accessed May 2023).

NICE health technology evaluations: the manual. Process and methods (PMG36) 2022. Online https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation (Accessed May 2023).

Karen M, Vishnu PW. PD48 Does Unmet Need Influence the Scottish Medicines Consortium Health Technology Assessment Decisions For Rare Disease Conditions? Online https://www.cambridge.org/core/journals/international-journal-of-technology-assessment-in-health-care/article/pd48-does-unmet-need-influence-the-scottish-medicines-consortium-health-technology-assessment-decisions-for-rare-disease-conditions/16EE12B6704F13803FEEAFCFE5656027 (Accessed May 2023).

García CH. Spanish routes for making available medicines to patients before authorisation. Online https://health.ec.europa.eu/system/files/2016-11/stamp_stamp_agenda_point_4_es_aemps_en_0.pdf (Accessed May 2023).

Regolamento UE. 2021/2282 del Parlamento Europeo e del Consiglio del 15 dicembre 2021 relativo alla valutazione delle tecnologie sanitarie e che modifica la direttiva 2011/24/UE. Online https://eur-lex.europa.eu/legal-content/IT/TXT/PDF/?uri=CELEX:32021R2282&from=EN (Accessed May 2023)